Having trouble accessing articles? Reset your cache.

Vivalis, GlaxoSmithKline, Texas A&M University System, U.S. Department of Health and Human Services infectious, biomanufacturing news

GlaxoSmithKline and the university announced that HHS has approved the establishment of a $91 million influenza-vaccines manufacturing facility in Bryan-College Station, Texas.

Read the full 224 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE